Mild cognitive impairment in parkinson's disease

Age and Ageing

Volumn 42, Issue 5, 2013, Pages 567-576

  Yarnall, Alison Jane ^a   Rochester, Lynn ^b   Burn, David John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Amyloid; Dementia; Mild cognitive impairment; Older people; Parkinson's disease

Indexed keywords

ATOMOXETINE; NEUROTRANSMITTER;

ALZHEIMER DISEASE; ARTICLE; ATTENTION DISTURBANCE; COGNITIVE THERAPY; DISEASE COURSE; HUMAN; KINESIOTHERAPY; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN AGGREGATION; RISK FACTOR; SCREENING TEST;

AMYLOID; DEMENTIA; MILD COGNITIVE IMPAIRMENT; OLDER PEOPLE; PARKINSON'S DISEASE;

AGE FACTORS; AGING; ANTIPARKINSON AGENTS; COGNITION; DEMENTIA; DISEASE PROGRESSION; HUMANS; MILD COGNITIVE IMPAIRMENT; NOOTROPIC AGENTS; PARKINSON DISEASE; PREVALENCE; RISK FACTORS;

EID: 84882681039     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/aft085     Document Type: Article

References (30)

1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
3. Levy G, Tang MX, Louis ED et al. The association of incident dementia with mortality in PD. Neurology 2002; 59: 1708-13.
4. Aarsland D, Bronnick K, Ehrt U et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.
5. Vossius C, Larsen JP, Janvin C, Aarsland D. The economic impact of cognitive impairment in Parkinson's disease. Mov Disord 2011; 26: 1541-4.
6. Rosenthal E, Brennan L, Xie S et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170-6.
7. Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psych Neur 2012; 25: 208-14.
8. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Norwegian ParkWest Study G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-6.
9. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006; 21: 1343-9.
10. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-98.
11. Aarsland D, Bronnick K, Williams-Gray C et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-9.
12. Foltynie T, Brayne CEG, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550-60.
13. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-45.
14. Caviness JN, Driver-Dunckley E, Connor DJ et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-7.
15. Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009; 16: 1278-84.
16. Mamikonyan E, Moberg PJ, Siderowf A et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord 2009; 15: 226-31.
17. Dalrymple-Alford JC, Livingston L, MacAskill MR et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Disord 2011; 26: 629-36.
18. Williams-Gray CH, Evans JR, Goris A et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
19. Adler CH, Caviness JN, Sabbagh MN et al. Heterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment. Acta Neuropathol 2010; 120: 827-8.
20. Weintraub D, Doshi J, Koka D et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011; 68: 1562-8.
21. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007; 34: 714-23.
22. Tiraboschi P, Hansen LA, Alford M et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54: 407-11.
23. Meyer PM, Strecker K, Kendziorra K et al. Reduced alpha 4 beta 2-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psych 2009; 66: 866-77.
24. Yarnall AJ, Rochester L, Baker MR et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in Parkinson's disease? Mov Disord 2013. doi:10.1002/mds.25360
25. Rochester L, Yarnall AJ, Baker MR et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012; 135: 2779-88.
26. Montine TJ, Shi M, Quinn JF et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010; 25: 2682-5.
27. Alves G, Bronnick K, Aarsland D et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010; 81: 1080-6.
28. Gomperts SN, Locascio JJ, Rentz D et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85-91.
29. Litvan I, Goldman JG, Troster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349-56.
30. Dalrymple-Alford JC, MacAskill MR, Nakas CT et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-25.